Press Releases
Bioneer Unveils MegaBase Synthesizer, Revolutionizing High-Throughput Gene Synthesis
관리자 / 2025-05-21
Bioneer Unveils MegaBase Synthesizer, Revolutionizing
High-Throughput Gene Synthesis with
Enhanced Capacity and Cost-Efficiency
DAEJEON, South Korea – May 21, 2025 – Bioneer Corporation (KOSDAQ: 064550), a pioneering biotechnology
company with over 30 years of expertise in molecular and synthetic biology,
today announced significant advancements in its gene synthesis capabilities,
highlighted by the features of its new MegaBase Synthesizer. This cutting-edge
system dramatically boosts oligo pool production and offers enhanced
cost-effectiveness, reinforcing Bioneer's position as a leader in the synthetic
biology field.
The newly detailed MegaBase Synthesizer is
a high-efficiency platform capable of simultaneously synthesizing a staggering
56,448 diverse oligo pools, designed for the assembly of up to 1,152 genes in a
single run within a day. This system utilizes advanced phosphoramidite
chemistry, and its high-density integration allows for the production of a
significantly higher number of oligo pools than enzyme-based synthesis methods.
Furthermore, it successfully addresses the low-concentration issues often
associated with microarray-based oligo synthesis, positioning it as a
groundbreaking parallel oligo synthesizer.
A key strategic advantage for Bioneer is
its in-house development and production of core raw materials used in the
synthesis process. This vertical integration allows the company to offer
high-quality gene synthesis services with highly competitive pricing.
Leveraging the MegaBase Synthesizer, Bioneer now boasts a maximum monthly oligo
pool production capacity of 50 megabases (Mb). The company also highlighted
that its 1/1000 scale synthesis process has led to a dramatic reduction in raw
material costs, further enhancing its service value.
"The MegaBase Synthesizer represents a
significant leap forward in our mission to provide researchers with powerful
and accessible tools for synthetic biology," said a Bioneer spokesperson.
"By combining high-throughput capacity with our cost-effective in-house
material production, we are breaking down barriers for large-scale genomic
projects."
This development complements Bioneer's
established advanced synthesis capabilities. The company utilizes
state-of-the-art synthesizers, including its proprietary HT-oligo™ Synthesizer
alongside the broader Megabase Synthesizer line, to efficiently support
large-scale synthetic biology projects.
Continued Commitment to Innovation and
Service Excellence
Bioneer’s gene synthesis service is built
on a foundation of proprietary technology and stringent quality control:
- Competitive and Transparent Pricing: Bioneer offers competitive pricing, with sequence lengths
below 400bp available at a flat price, and a fixed price per base pair for
sequences up to 100,000bp. This model supports cost-effective synthesis
for diverse project scales. Additional discounts of at least 15% for bulk
orders and B2B contracts are applied, with intellectual property securely
preserved.
- Proprietary Oligo Design Technology: Bioneer’s oligo design technology achieves a success rate
exceeding 99% for initial fragment assembly. The core algorithm of this
technology standardizes oligo lengths to overcome potential concentration
variances during synthesis and maximizes the efficiency of assembling
small fragments. This high success rate is key to developing fully
automated gene synthesis processes. In 2024, Bioneer secured R&D
funding from the Ministry of Trade, Industry and Energy (MOTIE) to develop
autonomous manufacturing systems using artificial intelligence, aiming to
automate the production of thousands of initial fragments with minimal
human intervention.
- Innovative Fragment Assembly Technology: Bioneer employs a range of advanced techniques:
- Gibson Assembly: For constructs
smaller than 3 kb.
- Proprietary Fragment Assembly: For
mid-sized constructs (3 kb to 15 kb), capable of assembling over 20
fragments concurrently. While conventional fragment assembly often
involves fragments of varying lengths, Bioneer's technology cuts
customer-ordered sequences into uniform sizes for assembly. This advanced
technique boosts efficiency and facilitates the synthesis of complex
genes.
- In Vivo Assembly: For large
constructs (15 kb to 100 kb), facilitating highly complex DNA sequence
synthesis.
- Single Colony-Based Verification for 100% Accuracy: Bioneer guarantees 100% sequence accuracy for synthesized
genes through Sanger sequencing of single colonies, delivering only
perfectly matched clones to customers.
- Comprehensive Additional Services:
Bioneer offers cloning services (into proprietary or customer vectors),
mutagenesis, mRNA synthesis (including 5’ capping and 3’ poly(A) tailing),
gene-to-protein synthesis, and custom donor DNA templates for CRISPR
applications. Complimentary codon optimization, Rapid Gene Synthesis, and
AccuGeneBlock DNA fragments further enhance their offerings.
Notes and Considerations: Pricing and turnaround times may be adjusted for complex sequences
(e.g., extreme GC content or repetitive sequences). Synthesis of potentially
hazardous sequences requires customer consent beforehand, and genes toxic to E.
coli are typically delivered as linear PCR products. Products and data are
archived for six months post-delivery unless customers request immediate
disposal.
Conclusion
With the enhanced capabilities of the MegaBase Synthesizer, Bioneer
significantly strengthens its robust and reliable gene synthesis solutions for
the synthetic biology community. These advancements in synthesis capacity,
coupled with competitive pricing, proprietary technologies, and stringent
quality control, position Bioneer to effectively meet the evolving needs of
researchers in academia, biotechnology, and the pharmaceutical industry
worldwide.
About Bioneer Corporation: Established in 1992, Bioneer Corporation is a pioneering
biotechnology company based in South Korea, with over 30 years of expertise in
molecular and synthetic biology. As the first Korean company to offer gene
synthesis services, Bioneer has developed a comprehensive range of services,
from oligonucleotide synthesis to protein production. ###